Edesa Biotech, Inc. (EDSA)

CA — Healthcare Sector
Peers: CRVS  HOTH  IMRN  KTTA  PSTV  SABS  SNOA  SNTI  SONN  VRPX 

Automate Your Wheel Strategy on EDSA

With Tiblio's Option Bot, you can configure your own wheel strategy including EDSA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol EDSA
  • Rev/Share 0.0
  • Book/Share 2.9288
  • PB 0.7682
  • Debt/Equity 0.0
  • CurrentRatio 15.729
  • ROIC -0.4167

 

  • MktCap 15816938.0
  • FreeCF/Share -1.0788
  • PFCF -2.7633
  • PE -2.0449
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -1.0309

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
EDSA
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has sold, in a private placement, an aggregate of 834 newly designated Series B-1 convertible preferred shares (“Series B-1 Preferred Shares”) and 3,468,746 common shares in a private placement priced at-the-market under the rules of the Nasdaq Stock Market. The purchase price per Preferred Share was $10,000 and the purchase price per common share was $1.92. Officers and directors of the Company purchased approximately $1.1 million of the …

Read More
image for news Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

About Edesa Biotech, Inc. (EDSA)

  • IPO Date 2010-06-21
  • Website https://www.edesabiotech.com
  • Industry Biotechnology
  • CEO Pardeep Nijhawan FRCPC,
  • Employees 16

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.